Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis
Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis in High Risk Patients: Searching for the Optimal Dose. A Prospective, Randomized Trial
Sponsor: American College of Gastroenterology
This PHASE2/PHASE3 trial investigates Post-ERCP Pancreatitis and is currently completed. American College of Gastroenterology leads this study, which shows 14 recorded versions since 2013 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
14 versions recorded-
Nov 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Nov 2024 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2_PHASE3
▶ Show 9 earlier versions
-
Dec 2021 — Dec 2022 [monthly]
Completed PHASE2_PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2_PHASE3
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
Jul 2019 — Aug 2019 [monthly]
Completed PHASE2_PHASE3
-
Nov 2018 — Jul 2019 [monthly]
Completed PHASE2_PHASE3
Status: Recruiting → Completed
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Nov 2017 — Jun 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2017 — Nov 2017 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Jul 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- American College of Gastroenterology
- Beth Israel Deaconess Medical Center
- Indiana University
- Medical University of South Carolina
- University of Michigan
- University of Texas
- Wake Forest University Health Sciences
For direct contact, visit the study record on ClinicalTrials.gov .